Investigation Report on China Temozolomide Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||337523|
|出版日期||內容資訊||英文 30 Pages
|Temozolomide的中國市場 Investigation Report on China Temozolomide Market, 2010-2019|
|出版日期: 2015年08月18日||內容資訊: 英文 30 Pages||
Temozolomide是Schering-Plough開發的動物膠腫 (神經膠質瘤) 的治療藥，1999年受FDA (美國食品藥物管理局) ，2000年受中國當局被認證。中國國內的Temozolomide的銷售額，2006年達到600萬人民幣，2014年達3億人民幣以上，以及2008∼2014年的年複合成長率(CAGR) 估計為約67％。
Among all anti-tumor drugs, alkylating agent boasts of the longest history of application. Since nitrogen mustard was used to treat malignant lymphoma in 1942, alkylating agent has become the first-line anti-tumor drug due to its cheap price. The major varieties of alkylating agent are temozolomide and oxaliplatin. First developed by Schering-Plough, temozolomide was approved by FDA to treat glioma in 1999 and entered China since 2000.
Having efficacy in glioma, leukemia, melanoma, lymphoma and solid tumor, temozolomide can easily penetrate through blood-brain barrier and stay stable in acid environment with a broad antitumor spectrum and low toxicity. And it can be taken orally in patients who have drug resistance to nitrosoureas.
According to relevant statistics, about 60% of primary brain tumors are malignant ones. The incidence of malignant brain tumor in China is 80-100/1 million and the annual number of new cases is over 200,000. Temozolomide has reported a remarkable growth in global sales since its debut.
According to CRI's market survey, the sales value of temozolomide in sample hospitals rose from about CNY 6 million in 2006 to over CNY 300 million in 2014 with CAGR during the period of 2008-2014 reaching up to 67%. In 2014, the generic drug of temozolomide made by Tasly was approved to enter the market. Currently, temozolomide products available in the Chinese market come from the following four companies: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd, Orion (Finland), Schering-Plough and Beijing SL Pharmaceutical Co., Ltd, among which the former three dominate the market and Orion (Finland) had the largest market share of about 50.5% for sales value in 2014.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: